EPAS1

endothelial PAS domain protein 1, the group of PAS domain containing|Basic helix-loop-helix proteins

Basic information

Region (hg38): 2:46293667-46386697

Links

ENSG00000116016NCBI:2034OMIM:603349HGNC:3374Uniprot:Q99814AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • erythrocytosis, familial, 4 (Strong), mode of inheritance: AD
  • autosomal dominant secondary polycythemia (Supportive), mode of inheritance: AD
  • erythrocytosis, familial, 4 (Moderate), mode of inheritance: AD
  • erythrocytosis, familial, 4 (Strong), mode of inheritance: AD
  • erythrocytosis, familial, 4 (Limited), mode of inheritance: AD

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Erthyrocytosis, familial 4ADHematologic; OncologicIndividuals can present with manifestations secondary to erythrocytosis (eg, a DVT has been described in one individual), and interventions related to erythrocytosis (eg, venesection) have been described as beneficial; Due to a reported increased risk of neoplasms (eg, pheochromocytoma/paraganglioma), awareness may allow early detection and management, which may decrease associated morbidity and mortalityHematologic; Oncologic7747773; 18184961; 18456918; 18378852; 23090011
While presentation is typically described in adulthood, surveillance and treatment may be indicated in the pediatric time period

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the EPAS1 gene.

  • Erythrocytosis, familial, 4 (2 variants)
  • not provided (1 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the EPAS1 gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
3
clinvar
509
clinvar
2
clinvar
514
missense
2
clinvar
1
clinvar
741
clinvar
49
clinvar
4
clinvar
797
nonsense
0
start loss
0
frameshift
1
clinvar
1
inframe indel
0
splice donor/acceptor (+/-2bp)
0
splice region
3
21
6
30
non coding
49
clinvar
24
clinvar
76
clinvar
149
Total 2 1 794 582 82

Variants in EPAS1

This is a list of pathogenic ClinVar variants found in the EPAS1 region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
2-46297151-G-C Benign (Jun 21, 2019)1277023
2-46297251-T-C Benign (Jun 15, 2019)1241092
2-46297264-G-C Benign (Jun 15, 2019)1275431
2-46297273-G-A Benign (Jun 15, 2019)1232911
2-46297440-G-A Familial erythrocytosis Uncertain significance (Jun 14, 2016)336218
2-46297441-C-T Erythrocytosis, familial, 4 Benign (Jun 15, 2019)336219
2-46297460-A-C Erythrocytosis, familial, 4 Uncertain significance (Jan 12, 2018)336220
2-46297511-G-A Erythrocytosis, familial, 4 Uncertain significance (Jan 12, 2018)895789
2-46297555-G-C Erythrocytosis, familial, 4 Uncertain significance (Jan 13, 2018)895790
2-46297561-C-CT Familial erythrocytosis Benign (Jun 14, 2016)336221
2-46297565-T-G Erythrocytosis, familial, 4 Uncertain significance (Jan 13, 2018)336222
2-46297596-C-A Erythrocytosis, familial, 4 Uncertain significance (Jan 13, 2018)336223
2-46297657-G-T Erythrocytosis, familial, 4 Uncertain significance (Jan 13, 2018)336224
2-46297675-C-G Erythrocytosis, familial, 4 Uncertain significance (Mar 16, 2018)895791
2-46297681-C-G Erythrocytosis, familial, 4 Uncertain significance (Jan 13, 2018)336225
2-46297712-A-C Erythrocytosis, familial, 4 Uncertain significance (Jan 13, 2018)336226
2-46297772-G-A Erythrocytosis, familial, 4 Benign (Feb 01, 2023)336227
2-46297774-G-T Erythrocytosis, familial, 4 Uncertain significance (Jan 12, 2018)336228
2-46297801-G-C Erythrocytosis, familial, 4 Uncertain significance (Jan 13, 2018)336229
2-46297810-C-G Erythrocytosis, familial, 4 Uncertain significance (Jan 12, 2018)336230
2-46297820-G-A Erythrocytosis, familial, 4 Uncertain significance (Jan 12, 2018)896076
2-46297826-C-T Erythrocytosis, familial, 4 Uncertain significance (Jan 12, 2018)336231
2-46297848-G-GC Familial erythrocytosis Benign (Sep 25, 2018)336232
2-46297908-G-A Erythrocytosis, familial, 4 Benign/Likely benign (Mar 01, 2022)336233
2-46297911-A-G Uncertain significance (Jan 01, 2022)1675778

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
EPAS1protein_codingprotein_codingENST00000263734 1693031
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
0.5960.4041257331141257480.0000596
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense-0.1544904811.020.00002995752
Missense in Polyphen110164.020.670672024
Synonymous-3.942762041.350.00001401662
Loss of Function4.50837.90.2110.00000203452

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.0001810.000181
Ashkenazi Jewish0.000.00
East Asian0.00005440.0000544
Finnish0.00009240.0000924
European (Non-Finnish)0.00004560.0000439
Middle Eastern0.00005440.0000544
South Asian0.00006530.0000327
Other0.0003460.000326

dbNSFP

Source: dbNSFP

Function
FUNCTION: Transcription factor involved in the induction of oxygen regulated genes. Heterodimerizes with ARNT; heterodimer binds to core DNA sequence 5'-TACGTG-3' within the hypoxia response element (HRE) of target gene promoters (By similarity). Regulates the vascular endothelial growth factor (VEGF) expression and seems to be implicated in the development of blood vessels and the tubular system of lung. May also play a role in the formation of the endothelium that gives rise to the blood brain barrier. Potent activator of the Tie-2 tyrosine kinase expression. Activation requires recruitment of transcriptional coactivators such as CREBBP and probably EP300. Interaction with redox regulatory protein APEX seems to activate CTAD (By similarity). {ECO:0000250, ECO:0000250|UniProtKB:P97481}.;
Disease
DISEASE: Erythrocytosis, familial, 4 (ECYT4) [MIM:611783]: An autosomal dominant disorder characterized by increased serum red blood cell mass, elevated serum hemoglobin and hematocrit, and normal platelet and leukocyte counts. {ECO:0000269|PubMed:18184961, ECO:0000269|PubMed:18378852, ECO:0000269|PubMed:19208626, ECO:0000269|PubMed:22367913}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Pathway
Renal cell carcinoma - Homo sapiens (human);Pathways in cancer - Homo sapiens (human);Adipogenesis;Transcriptional regulation of pluripotent stem cells;Amplification and Expansion of Oncogenic Pathways as Metastatic Traits;Focal Adhesion-PI3K-Akt-mTOR-signaling pathway;Type 2 papillary renal cell carcinoma;Oxygen-dependent asparagine hydroxylation of Hypoxia-inducible Factor Alpha;Signaling by PTK6;Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha;Regulation of gene expression by Hypoxia-inducible Factor;Regulation of Hypoxia-inducible Factor (HIF) by oxygen;Cellular response to hypoxia;Signal Transduction;Cellular responses to stress;Post-translational protein modification;Metabolism of proteins;HIF-2-alpha transcription factor network;PTK6 Expression;Cellular responses to external stimuli;Neddylation;Signaling by Non-Receptor Tyrosine Kinases (Consensus)

Recessive Scores

pRec
0.386

Intolerance Scores

loftool
0.0692
rvis_EVS
-0.88
rvis_percentile_EVS
10.54

Haploinsufficiency Scores

pHI
0.245
hipred
Y
hipred_score
0.786
ghis
0.544

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
S
essential_gene_gene_trap
N
gene_indispensability_pred
E
gene_indispensability_score
0.920

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Epas1
Phenotype
vision/eye phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); skeleton phenotype; immune system phenotype; respiratory system phenotype; liver/biliary system phenotype; embryo phenotype; pigmentation phenotype; growth/size/body region phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); homeostasis/metabolism phenotype;

Zebrafish Information Network

Gene name
epas1b
Affected structure
primary motor neuron
Phenotype tag
abnormal
Phenotype quality
decreased amount

Gene ontology

Biological process
angiogenesis;response to hypoxia;embryonic placenta development;blood vessel remodeling;regulation of heart rate;regulation of transcription by RNA polymerase II;transcription by RNA polymerase II;mitochondrion organization;signal transduction;visual perception;erythrocyte differentiation;lung development;norepinephrine metabolic process;surfactant homeostasis;regulation of transcription from RNA polymerase II promoter in response to oxidative stress;post-translational protein modification;positive regulation of transcription by RNA polymerase II;cell maturation;myoblast fate commitment;iron ion homeostasis;regulation of transcription from RNA polymerase II promoter in response to hypoxia;cellular response to hypoxia;positive regulation of cold-induced thermogenesis
Cellular component
nucleus;nucleoplasm;transcription factor complex;cytosol;nuclear speck
Molecular function
DNA-binding transcription factor activity, RNA polymerase II-specific;DNA-binding transcription activator activity, RNA polymerase II-specific;DNA binding;protein binding;transcription factor binding;histone acetyltransferase binding;sequence-specific DNA binding;protein heterodimerization activity